CARDINAL HEALTH INC Earnings Summary — Q3 2026
Cardinal Health Reports Robust Revenue Growth Despite Quarterly Profit Decline
Key Takeaways
- Revenue grew 11% year-over-year to $60.9 billion, indicating sustained demand in pharmaceutical distribution.
- Net income saw a significant decline of 25% compared to Q3 2025, falling to $380 million.
- Operating expenses spiked to $1.99 billion, primarily driven by a rise in 'Other Operating Expenses' to $333 million.
- Share count reduction continues, with diluted shares outstanding down 2% YoY to 236 million.
- Gross profit improved to $2.5 billion, but was offset by higher selling, general, and administrative costs.
- The company effectively operates with negative equity, making it dependent on operational liquidity and debt access.
- Operating margins remain razor-thin at less than 1%, leaving the firm vulnerable to even minor cost fluctuations.
Management Guidance
Management is focusing on a 'simplify and focus' strategy to stabilize the Medical segment and distance the core business from legal liabilities through 'non-GAAP' reporting metrics.
Sentiment Shift
Stable
Outlook
The outlook remains clouded by structural headwinds in medical supplies and the long-term payout schedule of opioid settlements, though medical segment optimization shows early signs of progress.
← Back to CARDINAL HEALTH INC AI analysis
Unlock the full report
Deep-dive sections, financial charts, AI chat and PDF export are available with Premium.
This summary is AI-generated from CARDINAL HEALTH INC's latest annual report and public disclosures. It is for informational purposes only and is not investment advice.